NYSE · CIK 0001367644
EBS Emergent BioSolutions Inc.
Insider trading from SEC Form 4. Last filing 5 d ago. Close $7.06 on Oct 9, 2026, +59% from the 52-week low and -49% from the high.
Last 90 days
Net insider value
-$146k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$146k by 2 insiders
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
EBSOct 9, 2026 · close 7.06
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Emergent BioSolutions Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | Donald W DeGolyer director sell | $126k 17,800 shares | -14% | +59% from low-49% from high | |
| 3Weak | Paul Anthony Williams SVP, Products Business sell | $20k 3,000 shares | -2% | +43% from low-54% from high | |
| 11Weak | Kathryn C Zoon director sell | $63k 7,086 shares | -9% | +108% from low-26% from high | |
| 31Weak | Donald W DeGolyer director sell | $68k 7,844 shares | -5% | +109% from low-26% from high | |
| 2Weak | Keith Katkin director sell | $49k 7,844 shares | -8% | +50% from low-47% from high | |
| 54Moderate | Joseph C Papa President and CEO buy | $350k 60,000 shares | +21% | +38% from low-51% from high | |
| 35Weak | Kathryn C Zoon director sell | $57k 10,000 shares | -18% | - | |
| 45Moderate | Neal Franklin Fowler director sell | $204k 35,000 shares | -26% | - | |
| 41Moderate | Donald W DeGolyer director sell | $273k 25,000 shares | -18% | - | |
| 39Weak | Marvin L White director sell | $171k 14,287 shares | -21% | - |
Congressional trades
1 trade in EBS disclosed by members of Congress under the STOCK Act. All congressional trades.
- Steve CohenHouse · D-TN · last Jan 10, 20250 bought
1 sold
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Steve Cohen House · D-TN | Sale | EBS Emergent BioSolutions Inc. Common Stock | $1,001 to $15k | Dec 11, 2024 / Jan 10, 2025 30 days after the trade | Clerk |
Transactions
The last 67 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | Donald W DeGolyer director | SOpen-market sale Common Stock10b5-1 | -17,800 | $7.09 | $126k | 111,921 | 5 d ago |
| Oct 1, 2026 | Paul Anthony Williams SVP, Products Business | SOpen-market sale Common Stock10b5-1 | -3,000 | $6.53 | $20k | 156,098 | 7 d ago |
| Aug 15, 2025 | Kathryn C Zoon director | SOpen-market sale Common Stock10b5-1 | -7,086 | $8.87 | $63k | 71,799 | Aug 18, 2025 |
| Aug 12, 2025 | Donald W DeGolyer director | SOpen-market sale Common Stock | -7,844 | $8.65 | $68k | 137,659 | Aug 13, 2025 |
| Jul 11, 2025 | William Hartzel SVP, Bioservices | FTax withholding Common Stock | -4,263 | $7.36 | $31k | 103,692 | Jul 15, 2025 |
| Jun 8, 2025 | Richard S Lindahl EVP, Chief Financial Officer | FTax withholding Common Stock | -2,733 | $6.63 | $18k | 296,492 | Jun 10, 2025 |
| Jun 8, 2025 | Paul Anthony Williams SVP, Products Business | FTax withholding Common Stock | -464 | $6.63 | $3,076 | 85,871 | Jun 10, 2025 |
| Jun 8, 2025 | Coleen Glessner EVP, Quality & Ethics, and CPL | FTax withholding Common Stock | -1,249 | $6.63 | $8,281 | 174,927 | Jun 10, 2025 |
| Jun 8, 2025 | William Hartzel SVP, Bioservices | FTax withholding Common Stock | -1,167 | $6.63 | $7,737 | 107,955 | Jun 10, 2025 |
| May 23, 2025 | Keith Katkin director | SOpen-market sale Common Stock10b5-1 | -7,844 | $6.30 | $49k | 86,431 | May 28, 2025 |
| May 13, 2025 | Joseph C Papa President and CEO | POpen-market purchase Common Stock | +60,000 | $5.83 | $350k | 342,500 | May 15, 2025 |
| Apr 30, 2025 | Neal Franklin Fowler director | AGrant or award Common Stock | +34,403 | $0.00 | $0 | 135,503 | May 2, 2025 |
| Apr 30, 2025 | Kathryn C Zoon director | AGrant or award Common Stock | +34,403 | $0.00 | $0 | 78,885 | May 2, 2025 |
| Apr 30, 2025 | Marvin L White director | AGrant or award Common Stock | +34,403 | $0.00 | $0 | 88,495 | May 2, 2025 |
| Apr 30, 2025 | Keith Katkin director | AGrant or award Common Stock | +34,403 | $0.00 | $0 | 94,275 | May 2, 2025 |
| Apr 30, 2025 | Zsolt Harsanyi Chairman | AGrant or award Common Stock | +34,403 | $0.00 | $0 | 123,732 | May 2, 2025 |
| Apr 30, 2025 | Louis W Sullivan director | AGrant or award Common Stock | +34,403 | $0.00 | $0 | 139,098 | May 2, 2025 |
| Apr 30, 2025 | Ronald Richard director | AGrant or award Common Stock | +34,403 | $0.00 | $0 | 105,517 | May 2, 2025 |
| Apr 30, 2025 | Donald W DeGolyer director | AGrant or award Common Stock | +34,403 | $0.00 | $0 | 145,503 | May 2, 2025 |
| Apr 30, 2025 | Sujata Tyagi Dayal director | AGrant or award Common Stock | +34,403 | $0.00 | $0 | 97,532 | May 2, 2025 |
| Apr 30, 2025 | Marvin L White director | AGrant or award Stock Option (Right to Buy)derivative | +15,824 | $0.00 | $0 | 41,572 | May 2, 2025 |
| Apr 30, 2025 | Ronald Richard director | AGrant or award Stock Option (Right to Buy)derivative | +15,824 | $0.00 | $0 | 41,572 | May 2, 2025 |
| Apr 30, 2025 | Neal Franklin Fowler director | AGrant or award Stock Option (Right to Buy)derivative | +15,824 | $0.00 | $0 | 41,572 | May 2, 2025 |
| Apr 30, 2025 | Zsolt Harsanyi Chairman | AGrant or award Stock Option (Right to Buy)derivative | +15,824 | $0.00 | $0 | 41,572 | May 2, 2025 |
| Apr 30, 2025 | Kathryn C Zoon director | AGrant or award Stock Option (Right to Buy)derivative | +15,824 | $0.00 | $0 | 41,572 | May 2, 2025 |
| Apr 30, 2025 | Keith Katkin director | AGrant or award Stock Option (Right to Buy)derivative | +15,824 | $0.00 | $0 | 41,572 | May 2, 2025 |
| Apr 30, 2025 | Louis W Sullivan director | AGrant or award Stock Option (Right to Buy)derivative | +15,824 | $0.00 | $0 | 41,572 | May 2, 2025 |
| Apr 30, 2025 | Donald W DeGolyer director | AGrant or award Stock Option (Right to Buy)derivative | +15,824 | $0.00 | $0 | 41,572 | May 2, 2025 |
| Apr 30, 2025 | Sujata Tyagi Dayal director | AGrant or award Stock Option (Right to Buy)derivative | +15,824 | $0.00 | $0 | 41,572 | May 2, 2025 |
| Apr 7, 2025 | Coleen Glessner EVP, Quality & Ethics, and CPL | FTax withholding Common Stock | -480 | $4.44 | $2,131 | 176,176 | Apr 9, 2025 |
| Apr 7, 2025 | William Hartzel SVP, Bioservices | FTax withholding Common Stock | -561 | $4.44 | $2,491 | 109,122 | Apr 9, 2025 |
| Mar 6, 2025 | William Hartzel SVP, Bioservices | AGrant or award Common Stock | +62,500 | $0.00 | $0 | 109,683 | Apr 9, 2025 |
| Mar 12, 2025 | Neal Franklin Fowler director | SOpen-market sale Common Stock | -35,000 | $5.83 | $204k | 101,100 | Mar 12, 2025 |
| Mar 12, 2025 | Kathryn C Zoon director | SOpen-market sale Common Stock | -10,000 | $5.73 | $57k | 44,482 | Mar 12, 2025 |
| Mar 12, 2025 | Joseph C Papa President and CEO | AGrant or award Employee Stock Options (Right to Buy)derivative | +250,000 | $0.00 | $0 | 1,282,500 | Mar 12, 2025 |
| Mar 12, 2025 | Joseph C Papa President and CEO | AGrant or award Employee Stock Options (Right to Buy)derivative | +250,000 | $0.00 | $0 | 1,532,500 | Mar 12, 2025 |
| Mar 6, 2025 | Coleen Glessner EVP, Quality & Ethics, and CPL | AGrant or award Common Stock | +62,500 | $0.00 | $0 | 176,656 | Mar 10, 2025 |
| Mar 6, 2025 | Jessica Perl SVP, General Counsel, Corp Sec | AGrant or award Common Stock | +62,500 | $0.00 | $0 | 68,387 | Mar 10, 2025 |
| Mar 6, 2025 | Paul Anthony Williams SVP, Products Business | AGrant or award Common Stock | +62,500 | $0.00 | $0 | 86,335 | Mar 10, 2025 |
| Mar 6, 2025 | Richard S Lindahl EVP, Chief Financial Officer | AGrant or award Common Stock | +146,888 | $0.00 | $0 | 299,225 | Mar 10, 2025 |
| Mar 6, 2025 | Simon C Lowry SVP, R&D, CMO | AGrant or award Common Stock | +62,500 | $0.00 | $0 | 91,982 | Mar 10, 2025 |
| Mar 6, 2025 | William Hartzel SVP, Bioservices | AGrant or award Common Stock | +62,500 | $0.00 | $0 | 109,975 | Mar 10, 2025 |
| Mar 6, 2025 | Joseph C Papa President and CEO | AGrant or award Common Stock | +282,500 | $0.00 | $0 | 282,500 | Mar 10, 2025 |
| Mar 6, 2025 | William Hartzel SVP, Bioservices | AGrant or award Employee Stock Options (Right to Buy)derivative | +62,500 | $0.00 | $0 | 214,711 | Mar 10, 2025 |
| Mar 6, 2025 | Simon C Lowry SVP, R&D, CMO | AGrant or award Employee Stock Options (Right to Buy)derivative | +62,500 | $0.00 | $0 | 102,999 | Mar 10, 2025 |
| Mar 6, 2025 | Richard S Lindahl EVP, Chief Financial Officer | AGrant or award Employee Stock Options (Right to Buy)derivative | +178,546 | $0.00 | $0 | 484,490 | Mar 10, 2025 |
| Mar 6, 2025 | Joseph C Papa President and CEO | AGrant or award Employee Stock Options (Right to Buy)derivative | +282,500 | $0.00 | $0 | 1,032,500 | Mar 10, 2025 |
| Mar 6, 2025 | Paul Anthony Williams SVP, Products Business | AGrant or award Employee Stock Options (Right to Buy)derivative | +62,500 | $0.00 | $0 | 210,114 | Mar 10, 2025 |
| Mar 6, 2025 | Jessica Perl SVP, General Counsel, Corp Sec | AGrant or award Employee Stock Options (Right to Buy)derivative | +62,500 | $0.00 | $0 | 95,945 | Mar 10, 2025 |
| Mar 6, 2025 | Coleen Glessner EVP, Quality & Ethics, and CPL | AGrant or award Employee Stock Options (Right to Buy)derivative | +62,500 | $0.00 | $0 | 249,613 | Mar 10, 2025 |
| Mar 5, 2025 | William Hartzel SVP, Bioservices | FTax withholding Common Stock | -292 | $5.80 | $1,694 | 47,183 | Mar 7, 2025 |
| Feb 28, 2025 | Paul Anthony Williams SVP, Products Business | FTax withholding Common Stock | -382 | $7.48 | $2,857 | 23,951 | Mar 4, 2025 |
| Feb 12, 2025 | Richard S Lindahl EVP, Chief Financial Officer | DDisposition to issuer Common Stock | -16,916 | $0.00 | $0 | 154,093 | Mar 4, 2025 |
| Feb 12, 2025 | Coleen Glessner EVP, Quality & Ethics, and CPL | DDisposition to issuer Common Stock | -5,913 | $0.00 | $0 | 138,547 | Mar 4, 2025 |
| Mar 1, 2025 | Paul Anthony Williams SVP, Products Business | FTax withholding Common Stock | -116 | $7.48 | $868 | 23,835 | Mar 4, 2025 |
| Feb 28, 2025 | Richard S Lindahl EVP, Chief Financial Officer | FTax withholding Common Stock | -1,073 | $7.48 | $8,026 | 153,020 | Mar 4, 2025 |
| Feb 12, 2025 | Coleen Glessner EVP, Quality & Ethics, and CPL | DDisposition to issuer Common Stock | -24,078 | $0.00 | $0 | 114,469 | Mar 4, 2025 |
| Mar 1, 2025 | Richard S Lindahl EVP, Chief Financial Officer | FTax withholding Common Stock | -683 | $7.48 | $5,109 | 152,337 | Mar 4, 2025 |
| Mar 1, 2025 | Coleen Glessner EVP, Quality & Ethics, and CPL | FTax withholding Common Stock | -313 | $7.48 | $2,341 | 114,156 | Mar 4, 2025 |
| Feb 9, 2025 | Jessica Perl SVP, General Counsel, Corp Sec | FTax withholding Common Stock | -918 | $10.00 | $9,180 | 5,887 | Feb 11, 2025 |
| Dec 15, 2024 | Simon C Lowry SVP, R&D, CMO | AGrant or award Common Stock | +29,482 | $0.00 | $0 | 29,482 | Dec 17, 2024 |
| Dec 15, 2024 | Simon C Lowry SVP, R&D, CMO | AGrant or award Employee Stock Option (Right to buy)derivative | +40,499 | $0.00 | $0 | 40,499 | Dec 17, 2024 |
| Dec 8, 2024 | Coleen Glessner EVP, Quality & Ethics, and CPL | FTax withholding Common Stock | -18,674 | $9.01 | $168k | 144,460 | Dec 10, 2024 |
| Nov 12, 2024 | Donald W DeGolyer director | SOpen-market sale Common Stock | -25,000 | $10.91 | $273k | 111,100 | Nov 14, 2024 |
| Nov 11, 2024 | William Hartzel SVP, Bioservices | FTax withholding Common Stock | -632 | $11.97 | $7,565 | 47,475 | Nov 13, 2024 |
| Nov 11, 2024 | Marvin L White director | SOpen-market sale Common Stock | -14,287 | $11.97 | $171k | 54,092 | Nov 13, 2024 |
| Oct 15, 2024 | Richard S Lindahl EVP, Chief Financial Officer | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 171,009 | Oct 17, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Sujata Tyagi Dayaldirector
- Donald W DeGolyerdirector
- Neal Franklin Fowlerdirector
- Coleen GlessnerEVP, Quality & Ethics, and CPL
- Zsolt HarsanyiChairman
- William HartzelSVP, Bioservices
- Keith Katkindirector
- Richard S LindahlEVP, Chief Financial Officer
- Simon C LowrySVP, R&D, CMO
- Joseph C PapaPresident and CEO
- Jessica PerlSVP, General Counsel, Corp Sec
- Ronald Richarddirector
- Louis W Sullivandirector
- Marvin L Whitedirector, ceo, president, officer
- Paul Anthony WilliamsSVP, Products Business
- Kathryn C Zoondirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.